Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics - sprookjes - yvandenbroek - TriplyDB

Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics

Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics

http://www.wikidata.org/entity/Q26822421

about

Emerging and future therapies for hemophilia Anti-infective immunoadhesins from plants.A perspective on the structure and receptor binding properties of immunoglobulin G Fc The Role of FcRn in Antigen Presentation Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy Bioconjugation of therapeutic proteins and enzymes using the expanded set of genetically encoded amino acids.Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype.Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applications Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.Regulation of immune responses by the neonatal fc receptor and its therapeutic implications Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates.FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.A noncytolytic antibody-like extendin-4-IgG4 fusion protein as a long-acting potential anti-diabetic agent.FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin.Weak protein interactions and pH- and temperature-dependent aggregation of human Fc1.Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases.Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding.Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.Changing paradigm of prophylaxis with longer acting factor concentrates.Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.Longer-acting clotting factor concentrates for hemophilia.Monoclonal antibodies: technologies for early discovery and engineering.Eftrenonacog Alfa: A Review in Haemophilia B.Quantification of IgG monoclonal antibody clearance in tissues.Antibody Engineering for Pursuing a Healthier Future Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model.Half-life extended biotherapeutics.Fcγ1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties.Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A.Calibrated flux measurements reveal a nanostructure-stimulated transcytotic pathway.The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.Efmoroctocog Alfa: A Review in Haemophilia A.The ever-expanding myokinome: discovery challenges and therapeutic implications.Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein.Recent advances in (therapeutic protein) drug development.Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.

P2860

Q26781143-9B0DA96E-6D7D-4D6E-ACAE-B30CA0A8C374 Q26799080-502B1372-3B3A-4446-B046-4E761C7B1AE7 Q26827579-6F30250B-E99F-4EC2-97D6-D9CC7C973D67 Q26852988-DA3F3B12-0E3B-49EF-960C-89BBBD19BFFE Q27321626-C8A210FC-5674-4061-838C-17D186A955F8 Q28257521-558152E0-3046-41DC-B883-300E7D645120 Q30279245-2BBD3F62-CDA7-47F8-AA08-A27301A3F676 Q30491639-57D464EA-8B2E-48FB-B096-5282944559A7 Q30834514-F0198DDF-5FFA-45DE-BC9F-96CFA784EEDA Q34045763-1D646739-A6B2-4CBF-B6AB-A4C51308B06A Q34818194-2035889F-4B02-4D8F-9597-8D7849E3A33A Q35168244-6DE4DF7E-CC70-4235-832A-2160553E3EAC Q35212305-BC205CC5-11E0-48C8-8C20-36D465AC7B20 Q35531873-B3C60E2A-1E67-4297-815B-6870FD9B148D Q35612397-DF450505-7C84-49DB-8419-355C0373F315 Q35643633-1C34FD4B-9A9E-4FFC-9158-308AC2D2F01A Q35670904-CA69778F-19A1-4AB0-B403-D36D1A42D3D9 Q35743857-66848733-89D2-4021-876F-45A361B69D63 Q36212739-A91F3DE4-0CD8-4A14-B34A-3A8FCE654C78 Q36214076-50346646-236D-40CC-9249-DFE279C5D145 Q36510864-0DEAFF18-548B-4DF7-8BD9-F1C271058E46 Q37489013-834984AA-494E-4EAC-80E6-C872AECA0EA3 Q38206858-3D3C0237-BFD8-4D49-AFA7-DD93865702C0 Q38400396-72F5F80D-9CB4-4ED0-9BA7-CAA8DEB15D4F Q38543283-7E958F29-4D11-4066-B837-11F29F82CA9B Q38633596-B6E07791-0725-4820-A48B-A0381F7B882D Q38711095-E6A02688-0F31-40F3-9A5F-61F04E62B06B Q38726179-9D5855A4-B83C-42A9-8A02-2EE4E452896B Q38731632-1AAD90B1-2069-438C-B34E-E90EF11A6CE4 Q38760836-996F55DD-8378-4F0F-91F6-8E22B5381465 Q38770067-6137D10D-DE48-42E7-BF31-9049C38371B6 Q38799374-50422937-715B-4F90-9F5C-EFFE36FE40E7 Q38828174-A417353B-0303-404B-A98F-EAC63AEBB8BA Q38846512-A38F39EB-78FB-49D5-A5E3-D3B088F3EEE9 Q38867485-24135FF0-184F-489B-8C10-0F839823DFDD Q38917306-CF32C694-48E5-44D1-A131-2EC73BFD592D Q38951385-B7C662AB-1506-4457-8AA3-BF991C46B19E Q38996905-6DDA85BF-E1A8-473D-8FA1-CD6DBA6EBC44 Q39148639-80A2AB54-C9EA-437C-BC2A-C690037A50FD Q39204747-8BD41E14-5FBF-4771-AE46-4D871C368D83

P2860

Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics

http://www.wikidata.org/entity/Q26822421

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Fc-fusion proteins and FcRn: s ...... nd more effective therapeutics

@ast

Fc-fusion proteins and FcRn: s ...... nd more effective therapeutics

@en

Fc-fusion proteins and FcRn: s ...... nd more effective therapeutics

@nl

type

label

Fc-fusion proteins and FcRn: s ...... nd more effective therapeutics

@ast

Fc-fusion proteins and FcRn: s ...... nd more effective therapeutics

@en

Fc-fusion proteins and FcRn: s ...... nd more effective therapeutics

@nl

prefLabel

Fc-fusion proteins and FcRn: s ...... nd more effective therapeutics

@ast

Fc-fusion proteins and FcRn: s ...... nd more effective therapeutics

@en

Fc-fusion proteins and FcRn: s ...... nd more effective therapeutics

@nl

P1433

Q26822421-0686ED7D-5D6E-4201-80E6-46C22C4F499F

P1476

Q26822421-C84E3484-BD83-453C-B7A0-FDD1FDF4F2C9

P2093

Q26822421-8450077C-D5E5-48F6-82D9-F3D235D9D331

Q26822421-8D7C4918-361D-4CC1-844E-058129F30F1C

Q26822421-C3DB3CBB-4FD9-4370-842D-DFCC496B12BC

Q26822421-E075A906-5FFE-4D89-ABBB-5512B5225006

Q26822421-EC78030E-ADAA-4D4F-A731-A2B9E0C752BF

Q26822421-F44431EA-6490-41E4-BF81-D02695EF0E47

P2860

Q26822421-00FCE82D-9937-4508-890C-B74BE9EE126E

Q26822421-033E4A80-F10F-4E60-82C4-88C57AEE8048

Q26822421-0466245F-D1B1-40B5-958D-2BAD7859D464

Q26822421-05505C30-A552-447D-BDBF-21E0E3D0ABE0

Q26822421-05A970E1-3508-4DEB-954E-6C4046E11184

Q26822421-099CA17F-DE28-4176-B3DA-4BB5333D7483

Q26822421-09FA5325-49CB-4757-A16D-8CA335D241EF

Q26822421-0B6474C1-8C81-40A0-BFD9-4394A226B224

Q26822421-15A72FC0-419C-4A01-800C-ECB90754E950

Q26822421-15E0D26C-BEA1-44E6-A980-DDC4C6BFABE3

P304

Q26822421-E06C925A-AB42-435B-BCFA-125B6CDD7448

P31

Q26822421-FCBFE35F-5A5E-4421-8311-23229BAB7B30

P3181

Q26822421-1B3775FE-3B7E-48BB-9111-7044E87CC35F

P356

Q26822421-333ADB59-DFB0-4348-8394-EC27431FE07A

P407

Q26822421-C600CD03-7A5B-4191-BB14-FD1619A3C9CD

P433

Q26822421-49BDB180-568F-4B63-8F39-21248FB0BDED

P478

Q26822421-1EAD16CF-0D52-4CAA-A85E-8FB9ADE8A364

P50

Q26822421-4F7C0BC7-5E7C-4F6B-8F54-76F632D39C54

Q26822421-89360755-BE42-42AB-BFBD-0887C60366C8

Q26822421-B2A18922-2958-4EA2-9A36-E76382FBADB8

P577

Q26822421-8AA4E564-EDB4-4FCB-BBFC-3794197F719F

P5875

Q26822421-37D1FD66-92AB-4A77-B599-CBF4879D88FE

P698

Q26822421-C02FEE06-7D3D-4788-A488-5D2DBFA8F413

P921

Q26822421-B92C125E-E309-4923-8A71-E6EE79647267

Q26822421-ECAB80D2-BAD1-42AB-B878-205EA7EAB4F5

P932

Q26822421-009A8378-4372-4D48-8E3A-153DEA02E406

P3181

P356

07388551.2013.834293

P1433

Critical Reviews in Biotechnology

P1476

Fc-fusion proteins and FcRn: s ...... nd more effective therapeutics

@en

P2093

Glenn F Pierce

http://www.w3.org/2001/XMLSchema#string

Haiyan Jiang

http://www.w3.org/2001/XMLSchema#string

Jennifer A Dumont

http://www.w3.org/2001/XMLSchema#string

Richard S Blumberg

http://www.w3.org/2001/XMLSchema#string

Robert T Peters

http://www.w3.org/2001/XMLSchema#string

Timo Rath

http://www.w3.org/2001/XMLSchema#string

P2860

A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"

The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan

The antiinflammatory activity of IgG: the intravenous IgG paradox

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical

Redistribution of the sheep neonatal Fc receptor in the mammary gland around the time of parturition in ewes and its localization in the small intestine of neonatal lambs

Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid

Continuous cultures of fused cells secreting antibody of predefined specificity

P304

235-254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2711142

http://www.w3.org/2001/XMLSchema#string

P356

10.3109/07388551.2013.834293

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

Wayne I. Lencer

P577

2013-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258041948

http://www.w3.org/2001/XMLSchema#string

P698

24156398

http://www.w3.org/2001/XMLSchema#string

P921

P932

4876602

http://www.w3.org/2001/XMLSchema#string